Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12868770 | 1.00 | TSHR (0.32) | TSHRROCK2ROCK1 | |
| SCHEMBL26492652 | 1.00 | TSHR (0.32) | TSHRROCK2ROCK1 | |
| SCHEMBL10885253 | 0.83 | ROCK2 (0.38) | ROCK2ROCK1 | |
| SCHEMBL13186237 | 0.83 | LMNA (0.35) | — | |
| SCHEMBL19014080 | 0.80 | — | — | |
| SCHEMBL15242463 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL12385831 | 0.79 | APLNR (0.39) | TSHR | |
| SCHEMBL11625869 | 0.79 | IDH1 (0.31) | ROCK2ROCK1 | |
| SCHEMBL11462533 | 0.79 | APLNR (0.39) | TSHR | |
| SCHEMBL12304003 | 0.79 | APLNR (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230139321-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170158703-A9 | METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-08 | — | — | US | disclosed |
| US-20160194331-A1 | METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20130252883-A1 | Macrocycles and Their Uses | NOVARTIS AG (CH) | 2013-09-26 | — | — | US | disclosed |
| US-8476224-B2 | Macrocycles and their uses | NOVARTIS AG (US) | 2013-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | TSHR 804/4885ROCK2 2361/4885ROCK1 2548/4885 |
| US-20160194331-A1 | METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE | MDM2, TP53, RB1 | TSHR 2130/4885ROCK2 2184/4885ROCK1 1126/4885 |
| US-20130252883-A1 | Macrocycles and Their Uses | MRPL21, CLPP, MLEC | TSHR 1888/4885ROCK2 2204/4885ROCK1 2782/4885 |
| US-20230139321-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | TSHR 804/4885ROCK2 2361/4885ROCK1 2548/4885 |
| US-20170158703-A9 | METHOD FOR PRODUCING SPIROOXINDOLE DERIVATIVE | MDM2, TP53, RB1 | TSHR 2130/4885ROCK2 2184/4885ROCK1 1126/4885 |
| US-20170198006-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | TSHR 3605/4885ROCK2 453/4885ROCK1 340/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | TSHR 2764/4885ROCK2 3141/4885ROCK1 1963/4885 |
| US-20230159580-A1 | PYRROLO[2,3-F]INDAZOLE AND 2,4,5,10-TETRAZATRICYCLO[7.3.0.03,7]DODECA-1,3(7),5,8,11-PENTAENE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINA3, SERPINC1 | TSHR 1629/4885ROCK2 2921/4885ROCK1 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.